NYSEMaterialsAgricultural InputsSnapshot 2026-07-31
Reading FMC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Reduce debt by about $1 billion: metric not reported.
View ThesisRevenue is contracting — down about 21% over the past year.
View GrowthManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 75% in its worst 12-month stretch.
View RiskFMC's growth depends on stabilizing its balance sheet and improving profitability. Recent earnings showed a beat with a 24% surprise, but revenue fell 17% year over year. It trades at 5.6× P/E, which is below the 18.9× peer median. This suggests the market expects less growth than what FMC could achieve. A key risk is the need to reduce debt by about $1 billion. Peer multiples imply a price about 49% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. FMC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering FMC (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for FMC in the last 4 months.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Fertilizers & Agricultural Chemicals — fair value, gap to price, and forward P/E.
Threatens: Announce and execute share buyback program
Cuts outlook indicates potential difficulties in executing share buyback.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $10.71
The last 12 months of price, then the range of analyst 12-month targets from today’s $10.71.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive growth of new active ingredients
New active ingredient approval supports growth strategy.
Threatens: Strengthen balance sheet by reducing debt by $1 billion
Debt solution raises concerns about balance sheet strength.
Strategic investment may enhance growth and validate market position.
Advances: Explore strategic options including potential sale
Strategic partnership enhances growth potential through new product offerings.
Advances: Explore strategic options including potential sale
Sale of India business aligns with strategic options exploration.
Advances: Strengthen balance sheet by reducing debt by $1B
Debt paydown target supports balance sheet strengthening objective.
Advances: Drive growth of new active ingredients
Approval for Isoflex supports growth of new active ingredients.
